Insider sales are trivial relative to market cap and likely driven by routine diversification or tax planning. Hoge's sale may be tied to a 10b5-1 plan given the single large block. No bearish signal, ignore for trading purposes.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 26 $46.99entry
- T+1 · 6mo ago +1.04%α +1.03% · $47.48
- T+5 · 6mo ago −2.96%α −4.17% · $45.60
- T+20 · 5mo ago +29.81%α +32.08% · $61.00
- T+60 · 3mo ago +271.09%α +268.63% · $174.38
Price Chart
How similar events traded
Executive Summary
Two Moderna insiders sold a total of $3.02M in open-market sales over a 7-day window. Director Noubar Afeyan exercised and sold 9,263 shares for $434K, while President Stephen Hoge sold 53,300 shares for $2.58M. The total sales represent ~0.016% of Moderna's $18.8B market cap, a trivial amount that does not signal material insider concern.
Key Financial Metrics
Key Facts
- Two insiders sold a combined $3.02M in open-market sales over 7 days
- President Stephen Hoge sold 53,300 shares at $48.40 for $2.58M on 2026-05-15
- Director Noubar Afeyan sold 9,263 shares at $46.84 for $434K on 2026-05-21
- Total sales represent ~0.016% of Moderna's $18.8B market cap
- Afeyan's sale followed derivative exercises at $0 and $19.15 per share (non-cash acquisition)
- No insider purchases were reported in the cluster
Financial Impact
Total insider sales of $3.02M, representing 0.016% of market cap
Risk Factors
- Insider sales could increase if stock rallies further, but current level is immaterial
- No insider buying to offset the selling pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MRNA-1779490839769 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers